C2N Diagnostics, LLC is a company specializing in diagnostic tools aimed at improving Alzheimer’s disease detection through innovative approaches. Recently, the company expanded its global presence by forming new partnerships with healthcare providers interested in using its PrecivityAD2 blood test. This non-invasive test uses a simple blood sample to identify the presence or absence of amyloid pathology, a key indicator of Alzheimer’s disease. It is intended for people aged 55 and older who show signs or symptoms of cognitive decline and are being evaluated for Alzheimer’s or other causes of memory loss.
Health Technology Insights: Pager Health Unveils AI Behavioral Health Agent to Simplify Care Access
The company has signed agreements with six additional clinical reference laboratories and distributors, expanding its testing services to over seven new countries. The new partners include Accuserv Diagnostic Center in the Philippines, Archerfish Precision Diagnostics in Singapore and other parts of Southeast Asia, Codex Genetics in Hong Kong, Dr. Dangs Lab in India, Medical Link in Israel, and Milenia Labs in Costa Rica and Mexico. These partnerships complement C2N’s existing relationships with major labs such as Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, along with a research collaboration with Mediford.
Health Technology Insights: DialCare Announces Partnership With Zelis to Expand Access to Telehealth Solutions
Dr. Joel Braunstein, CEO of C2N Diagnostics, shared his thoughts on the expansion. He explained that these new international partnerships aim to improve access to C2N’s Precivity blood tests in regions facing healthcare challenges due to aging populations, a shortage of dementia specialists, and limited PET imaging availability. He added that these partnerships reflect the strong scientific research behind the tests, which have already helped healthcare providers deliver clearer diagnoses of Alzheimer’s to patients and their families in many countries. With Alzheimer’s disease on the rise, he emphasized the need for healthcare systems to adopt affordable and accessible diagnostic methods and expressed C2N’s commitment to supporting more patients globally in receiving early and accurate diagnoses.
The PrecivityAD2 blood test has undergone extensive validation for both analytical and clinical performance. Its accuracy was highlighted in a large clinical study published in the Journal of the American Medical Association (JAMA), which examined how the test could enhance early Alzheimer’s diagnosis in primary care settings, where most patients first seek help for memory issues. The study demonstrated that the PrecivityAD2 test achieved over 90 percent diagnostic accuracy at a specific cutoff, comparing favorably to traditional methods such as cerebrospinal fluid analysis and amyloid PET scans.
All of C2N’s Precivity tests are performed under the ISO 13485:2016 quality management system in a laboratory that is both CLIA certified and CAP accredited. By expanding its global network of partnerships, C2N aims to make Alzheimer’s disease diagnosis more accessible, timely, and affordable for healthcare providers and patients around the world.
Health Technology Insights: Intas, Accord BioPharma Acquire UDENYCA to Expand Globally
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
